BPTS vs. ARDS, NBY, ARAV, ATXI, CYCC, CLVR, AGRX, SXTP, ONCO, and VRPX
Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Aridis Pharmaceuticals (ARDS), NovaBay Pharmaceuticals (NBY), Aravive (ARAV), Avenue Therapeutics (ATXI), Cyclacel Pharmaceuticals (CYCC), Clever Leaves (CLVR), Agile Therapeutics (AGRX), 60 Degrees Pharmaceuticals (SXTP), Onconetix (ONCO), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical preparations" industry.
Biophytis (NASDAQ:BPTS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.
Biophytis has a net margin of 0.00% compared to Aridis Pharmaceuticals' net margin of -5.11%.
Biophytis has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Biophytis presently has a consensus target price of $600.00, suggesting a potential upside of 7,199.27%. Aridis Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 3,439.82%. Given Biophytis' higher probable upside, research analysts clearly believe Biophytis is more favorable than Aridis Pharmaceuticals.
Biophytis has higher earnings, but lower revenue than Aridis Pharmaceuticals.
In the previous week, Biophytis' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
0.1% of Biophytis shares are held by institutional investors. Comparatively, 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aridis Pharmaceuticals received 116 more outperform votes than Biophytis when rated by MarketBeat users. However, 100.00% of users gave Biophytis an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Summary
Biophytis and Aridis Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.
Get Biophytis News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biophytis Competitors List
Related Companies and Tools
